Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN58,3558,41,13
Msft-0,51
Nokia4,544,8190,34
IBM0,81
Mercedes-Benz Group AG61,6861,70,29
PFE-0,43
17.02.2025 18:00:46
Indexy online
AD Index online
select
AD Index online
 

  • 15.02.2025 2:00:00
CryoPort (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
6,73 0,37 0,03 170 868
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace:
Popis společnosti
Obecné informace
Název společnostiCryoPort Inc
TickerCYRX
Kmenové akcie:Ordinary Shares
RICCYRX.O
ISIN-
Prioritní akcieConv. Pref. Shrs Class A
Prioritní akcieConv. Pref. Shrs Class B
Prioritní akciePreference Shares Class C
Poslední známé roční výsledky31.12.2022
Poslední známé čtvrtletní výsledky30.09.2023
Počet zaměstnanců k 31.12.2022 960
Akcie v oběhu k 30.09.2023 48 963 717
MěnaUSD
Kontaktní informace
Ulice112 Westwood Place, Suite 350
MěstoBRENTWOOD
PSČ37027
ZeměUnited States
Kontatní osobaScott Eckstein
Funkce kontaktní osobyInvestor Relations
Telefon19 492 321 900
Fax19494702306

Business Summary: Cryoport, Inc. is a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Its global platform provides mission-critical solutions, services, and products to the biopharma/pharma, animal health, and reproductive medicine markets worldwide. It provides supply chain technologies and services through its brands, including Cryoport Systems, IntegriCell, CryoStork, MVE Biological Solutions, CRYOPDP, and CRYOGENE. Its products include Cryoport Express Shippers, Cryoport ELITE Shipper Systems, Cryoport Consulting Services, Cryoport Bioservices, CRYOGENE, CRYOPDP Temperature-controlled Logistics and IntegriCell Services. In the biopharma/pharma market, it is focused on supporting biopharma/pharma companies. CRYOGENE provides unparalleled solutions for the provision of pre-clinical temperature-controlled biological materials management services to the life sciences industry.
Financial Summary: BRIEF: For the nine months ended 30 September 2023, CryoPort Inc revenues decreased 1% to $176M. Net loss applicable to common stockholders increased 27% to $43.2M. Revenues reflect Reproductive medicine segment decrease of 46% to $7.7M, Europe & Middle East & Africa (EMEA) segment decrease of 3% to $47.5M, Americas segment decrease of 1% to $96.4M.
Odvětvová klasifikace
TRBC2009Medical Equipment / Supplies / Distribution
TRBC2012Freight Logistics
RBSS2004Containers & Packaging
MGINDUSTRYMisc. Transportation
MGSECTORTransportation
NAICSFreight Transportation Arrangement
NAICSProcess, Physical Distribution, and Logistics Consulting Services
NAICS2007Freight Transportation Arrangement
NAICS2007Process, Phys Dist & Log Consulting Services
NAICS1997Freight Transportation Arrangement
NAICS1997Process, Physical, Distribution and Logistics Consulting Services
SICPlastics Foam Products
SICFreight Trans Arrangement
SICManagement Consulting Services



  • Poslední aktualizace:
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, President, Chief Executive OfficerJerrell Shelton7705.11.2012
Chief Financial Officer, Senior Vice President, Chief Administrative OfficerRobert Stefanovich5827.06.2011
Senior Vice President, Chief Digital and Technology OfficerEdward Zecchini6219.02.202419.02.2024
Senior Vice President, Chief Scientific OfficerMark Sawicki-